Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma

Histone deacetylase inhibitors enhance oncolytic herpes simplex virus therapy for malignant meningioma

Approximately 20% of meningiomas are not benign (higher grade) and tend to relapse after surgery and radiation therapy. Malignant (anaplastic) meningioma (MM) is a minor subset of high-grade meningioma that is lethal with no effective treatment options currently. Oncolytic herpes simplex virus (oHSV...

Full description

Bibliographic Details
Main Authors: Yoichiro Kawamura, Lingyang Hua, Alessandra Gurtner, Ego Wong, Juri Kiyokawa, Nadia Shah, Joshua Gorham, Hiroko Wakimoto, Samuel D. Rabkin, Robert L. Martuza, Hiroaki Wakimoto
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Meningioma
Malignant meningioma
Oncolytic herpes simplex virus
Histone deacetylase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S075333222201232X

Internet

http://www.sciencedirect.com/science/article/pii/S075333222201232X

Similar Items